Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0033 USD | -10.81% | 0.00% | -8.33% |
Valuation
Fiscal Period: March | 2022 | 2023 |
---|---|---|
Capitalization 1 | 173.1 | 35.27 |
Enterprise Value (EV) 1 | 173.3 | 36.67 |
P/E ratio | -26.2 x | -20.2 x |
Yield | - | - |
Capitalization / Revenue | - | - |
EV / Revenue | - | - |
EV / EBITDA | - | - |
EV / FCF | 90,789,391 x | -57,809,905 x |
FCF Yield | 0% | -0% |
Price to Book | 16.2 x | 3.49 x |
Nbr of stocks (in thousands) | 786,633 | 807,048 |
Reference price 2 | 0.2200 | 0.0437 |
Announcement Date | 6/10/22 | 7/10/23 |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales | - | - | - |
EBITDA | - | - | - |
EBIT 1 | -0.3416 | -6.471 | -1.697 |
Operating Margin | - | - | - |
Earnings before Tax (EBT) 1 | -0.343 | -6.471 | -1.897 |
Net income 1 | -0.343 | -6.471 | -1.742 |
Net margin | - | - | - |
EPS | - | -0.008404 | -0.002160 |
Free Cash Flow | - | 1.908 | -0.6344 |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 10/19/21 | 6/10/22 | 7/10/23 |
Balance Sheet Analysis
Fiscal Period: March | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt 1 | 0.03 | 0.2 | 1.41 |
Net Cash position 1 | - | - | - |
Leverage (Debt/EBITDA) | - | - | - |
Free Cash Flow | - | 1.91 | -0.63 |
ROE (net income / shareholders' equity) | - | -127% | -16.6% |
ROA (Net income/ Total Assets) | - | -66.7% | -8.66% |
Assets 1 | - | 9.703 | 20.13 |
Book Value Per Share | - | 0.0100 | 0.0100 |
Cash Flow per Share | - | 0 | 0 |
Capex | - | - | - |
Capex / Sales | - | - | - |
Announcement Date | 10/19/21 | 6/10/22 | 7/10/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-8.33% | 4.78M | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-2.21% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |
- Stock Market
- Equities
- ABTI Stock
- Financials Alterola Biotech, Inc.